About Verge Genomics
Verge Labs is a biotechnology company pioneering the application of frontier artificial intelligence to human biology, with a primary focus on neurological diseases. Over the past decade, the company has assembled one of the world's largest proprietary collections of multi-modal patient brain data, comprising deep molecular profiling on 12,000+ brains across 6,000+ patients. This dataset includes paired proteomic, genomic, and clinical data, plus a physical inventory of 900+ frozen brain tissue samples spanning major neurodegenerative diseases. The company has developed vBx-1.0, a breakthrough multi-modal foundation model for precision neurology that functions as a 'virtual biopsy' of the brain. This model can predict brain activity, therapy response, and side effects in patients with up to 3x greater accuracy than previous state-of-the-art models. By reconstructing what's happening inside a patient's brain from routine blood draws, the platform enables precision medicine approaches in neurology. Verge Labs' CONVERGE platform serves as an AI operating system for neuroscience drug development, addressing critical questions around target discovery, target characterization, biomarker identification, and patient stratification. The company has established $1.6B in partnerships with top-20 pharmaceutical companies and has advanced two AI-discovered drugs to clinical candidate stage, including VRG50635, which completed a Phase 1b trial in ALS in late 2025. The platform has surfaced 280+ novel drug targets with an 83% preclinical validation rate, demonstrating the power of starting drug discovery directly in human tissue rather than relying on animal models or cell culture systems.
Mission & Story
Mission
Over the last decade, we have built one of the largest proprietary collections of multimodal patient brain data. We've used that data to train foundation models that can reason about what's happening inside a patient's brain, and predict how it will change with treatment. We're now using that platform to usher in a new era of precision neurology, where we can predict which targets to drug, and in which patients.
Clinical Focus
Medical conditions and clinical areas addressed by Verge Genomics.
Who It Serves
Milestones & Awards
Recent Milestones
June 2026: Released vBx-1.0 foundation model for precision neurology. Late 2025: Completed Phase 1b trial for VRG50635 in ALS. Two AI-discovered drugs reached clinical candidate stage. 280+ novel drug targets surfaced.
Key Partnerships
Company Details
- Headquarters
- San Francisco, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.